subscribeSubscribe
U.S. Government Exercises Option to Purchase Additional RAPIVAB from BioCryst

U.S. Government Exercises Option to Purchase Additional RAPIVAB from BioCryst
GLOBENEWSWIRE
25 Aug 2022
Share Share
U.S. Government Exercises Option to Purchase Additional RAPIVAB from BioCryst

U.S. Government Exercises Option to Purchase Additional RAPIVAB from BioCryst
GLOBENEWSWIRE
01 Sep 2021
Share Share
BioCryst Announces FDA Approval of Supplemental NDAfor RAPIVAB®

BioCryst Announces FDA Approval of Supplemental NDAfor RAPIVAB®
BIOSPACE
03 Feb 2021
Share Share
BioCryst wins approval HAE pill charges half-a-M dollars, will anyone take it?

BioCryst wins approval HAE pill charges half-a-M dollars, will anyone take it?
Jason Mast ENDPTS
07 Dec 2020
Share Share
BioCryst Announces Full Exercise of Underwriters’ Option

BioCryst Announces Full Exercise of Underwriters’ Option
BIOSPACE
18 Nov 2019
Share Share
BioCryst Announces APeX-1 Clinical Trial Results for BCX7353 Published in NEJM

BioCryst Announces APeX-1 Clinical Trial Results for BCX7353 Published in NEJM
GLOBENEWSWIRE
30 Jul 2018
Share Share
Biocryst UK `s Alpivab (Peramivir) Receives Approval In Europe

Biocryst UK `s Alpivab (Peramivir) Receives Approval In Europe
EMA
26 Apr 2018
Share Share
Five new medicines backed for EU approval

Five new medicines backed for EU approval
Selina McKee PHARMA TIMES
26 Feb 2018
Share Share
EMA’s CHMP Recommends Five New Medicines for Approval

EMA’s CHMP Recommends Five New Medicines for Approval
Ana Mulero RAPS
26 Feb 2018
Share Share
Five medicines recommended for approval, including two orphans

Five medicines recommended for approval, including two orphans
EMA
23 Feb 2018
Share Share